Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study.

Détails

Ressource 1Télécharger: BIB_8289BEB90EE5.P001.pdf (199.86 [Ko])
Etat: Public
Version: de l'auteur⸱e
ID Serval
serval:BIB_8289BEB90EE5
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study.
Périodique
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
Auteur⸱e⸱s
Balaskas K., Vaudaux J., Boillat-Blanco N., Guex-Crosier Y.
ISSN
1234-1010
ISSN-L
1643-3750 (Electronic)
Statut éditorial
Publié
Date de publication
2012
Peer-reviewed
Oui
Volume
18
Numéro
5
Pages
CR296-CR302
Langue
anglais
Notes
Publication types: Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Résumé
BACKGROUND: The purpose of this pilot study is to compare the efficacy and tolerance of azithromycin alone as opposed to standard treatment with sulfadiazine and pyrimethamine for active, non-vision-threatening toxoplasmic retinochoroiditis.
MATERIAL/METHODS: We conducted a prospective, randomized, institutional clinical study comparing azithromycin to sulfadiazine and pyrimethamine for active, non-vision-threatening toxoplasmic retinochoroiditis. Nineteen out of 75 patients fulfilled inclusion criteria and were randomized into 2 treatment regimens. Nine patients were treated with sulfadiazine and pyrimethamine and 10 patients with azithromycin at a dose of 500 mg qd. Main outcome measures assessed were time to sharpening of lesion borders, time to lesion scarring, time to disease inactivity, and treatment tolerance.
RESULTS: Azithromycin monotherapy achieved lesion scarring and disease inactivity in all but 1 patient. Although no statistically significant difference was found between the 2 patient groups as regards main outcome measures for treatment efficacy, all median times to endpoints (days) were longer for the azithromycin group - time to sharpening of lesion borders on clinical evaluation (25.5 vs. 24) and masked evaluation of photographs (30.5 vs. 24), time to lesion scarring on clinical evaluation (73 vs. 47) and masked evaluation of photographs (71.5 vs. 36) and time to disease inactivity (73 vs. 49). Treatment tolerance was significantly better for the azithromycin group (p=0.0005). ConcluSIONS: Azithromycin monotherapy at a dose of 500 mg per day was shown to be effective and well-tolerated for the treatment of active, non-vision-threatening toxoplasmic retinochoroiditis. Duration of treatment was clinically longer for the azithromycin group.
Mots-clé
Adult, Antiprotozoal Agents/therapeutic use, Azithromycin/therapeutic use, Chorioretinitis/drug therapy, Chorioretinitis/physiopathology, Female, Humans, Male, Middle Aged, Pilot Projects, Prospective Studies, Pyrimethamine/therapeutic use, Sulfadiazine/therapeutic use, Toxoplasmosis, Ocular/drug therapy, Toxoplasmosis, Ocular/physiopathology
Pubmed
Web of science
Création de la notice
08/05/2012 15:33
Dernière modification de la notice
20/08/2019 15:42
Données d'usage